Well Referenced

Tag: adverse drug reactions

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration

This 2022 pharmacovigilance study analyzed FDA Adverse Event Reporting System (FAERS) data to assess the association between GLP-1 receptor agonists (GLP-1 RAs) and acute cholecystitis. The analysis revealed a notable number of reports linking GLP-1 RAs, such as liraglutide and semaglutide, to cases of acute cholecystitis. The proposed mechanism involves

Read More »
June 26, 2025 No Comments

Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology

This study investigates the safety and adverse effects of intratumoral (IT) mistletoe injections in 123 cancer patients, examining the incidence and severity of adverse drug reactions (ADRs) from 862 injections using preparations like Abnoba Viscum and Helixor. The study found that 21.1% of patients experienced mild ADRs, including localized reactions

Read More »
June 26, 2025 No Comments

Adverse Drug Reactions and Expected Effects to Therapy With Subcutaneous Mistletoe Extracts (Viscum Album L.) in Cancer Patients

This observational study assessed the safety and adverse drug reactions (ADRs) of subcutaneous mistletoe (Viscum album) extract in cancer patients. A total of 1,923 patients receiving mistletoe as part of anthroposophic medicine were observed, with 14.7% reporting expected effects such as local reactions and mild fever. Only 8.4% of patients

Read More »
June 26, 2025 No Comments

Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland

This multicenter, retrospective cohort study evaluated the long-term safety and effectiveness of standardized European mistletoe extract (Viscum album L., Iscador) as an adjuvant to conventional oncologic therapy in 1,442 patients with primary non-metastasized breast cancer (UICC stage I–III). Over a median follow-up of 67 months, patients receiving mistletoe extract in

Read More »
June 26, 2025 No Comments

Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients

This 2017 observational study (Phytomedicine, PMID: 29157828) evaluated immune-related and adverse drug reactions (ADRs) to low versus high initial doses of Viscum album L. (European mistletoe) in cancer patients. Higher starting doses were associated with increased immune responses, including mild fever and local inflammation, which were indicative of the desired

Read More »
June 26, 2025 No Comments

Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects

This 2012 observational study published in the Journal of Clinical Psychiatry (PMID: 22939118) examined the mental health of 61 former finasteride users who developed persistent sexual side effects after discontinuation. Results showed that 75% of these men had depressive symptoms (BDI-II ≥ 14), and 44% reported suicidal thoughts—dramatically higher than

Read More »
June 26, 2025 No Comments

Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems

The study titled “Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems” (Clinical Nutrition, 2021, PMID: 32778460) is an observational study analyzing 116 reports of adverse reactions (ARs) to α-lipoic acid (ALA) supplements collected by the Italian Phytovigilance System from 2002 to 2020. The majority

Read More »
June 26, 2025 No Comments